SF 4138

Introduction - 94th Legislature (2025 - 2026)

Posted on 03/05/2026 09:42 a.m.

A bill for an act
relating to health; providing a definition for covered insulin for the insulin safety
net program and manufacturer registration fee; amending Minnesota Statutes 2024,
sections 13.381, subdivision 20; 151.74, subdivisions 1, 2, 3, 4, 5, 6, 7, 9, 10, 11,
13, 14; 151.741, subdivisions 1, 2; Minnesota Statutes 2025 Supplement, section
151.741, subdivision 5; repealing Minnesota Statutes 2024, section 151.74,
subdivision 15.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2024, section 13.381, subdivision 20, is amended to read:

Subd. 20.

Insulin safety net.

Data collected relating to an individual who seeks to access
urgent-need new text begin covered new text end insulin or participates in a manufacturer's patient assistance program
is classified under section 151.74, subdivision 11.

Sec. 2.

Minnesota Statutes 2024, section 151.74, subdivision 1, is amended to read:

Subdivision 1.

Establishment.

(a) deleted text begin By July 1, 2020, deleted text end Each manufacturer must establish
procedures to make new text begin covered new text end insulin available in accordance with this section to eligible
individuals who are in urgent need of new text begin covered new text end insulin or who are in need of access to an
affordable new text begin covered new text end insulin supply.

(b) For purposes of this section, the following definitions apply:

(1) "manufacturer" means a manufacturer engaged in the manufacturing of new text begin covered
new text end insulin deleted text begin that is self-administered on an outpatient basis deleted text end ;

(2) "MNsure" means the Board of Directors of MNsure established in chapter 62V;

(3) "navigator" has the meaning provided in section 62V.02; deleted text begin and
deleted text end

(4) "pharmacy" means a pharmacy located in Minnesota and licensed under section
151.19 that operates in the community or outpatient license category under Minnesota Rules,
part 6800.0350 deleted text begin . deleted text end new text begin ; and
new text end

new text begin (5) "covered insulin" means a drug that is validly prescribed by a practitioner and contains
insulin for use to treat diabetes. Covered insulin does not include an insulin product with a
label approved by the United States Food and Drug Administration that indicates the product
is only for use for intravenous infusion.
new text end

(c) Any manufacturer with an annual gross revenue of $2,000,000 or less from new text begin covered
new text end insulin sales in Minnesota is exempt from this section. To request a waiver under this
paragraph, the manufacturer must submit a request to the Board of Pharmacy that includes
documentation indicating that the manufacturer is eligible for an exemption.

(d) deleted text begin An deleted text end new text begin A covered new text end insulin product is exempt from this section if the wholesale acquisition
cost of the new text begin covered new text end insulin is $8 or less per milliliter or applicable National Council for
Prescription Drug Plan billing unit, for the entire assessment time period, adjusted annually
based on the Consumer Price Index.

Sec. 3.

Minnesota Statutes 2024, section 151.74, subdivision 2, is amended to read:

Subd. 2.

Eligibility for urgent-need safety net program.

(a) To be eligible to receive
an urgent-need supply of new text begin covered new text end insulin under this section, an individual must attest to:

(1) being a resident of Minnesota;

(2) not being enrolled in medical assistance or MinnesotaCare;

(3) not being enrolled in prescription drug coverage that limits the total amount of
cost-sharing that the enrollee is required to pay for a 30-day supply of new text begin covered new text end insulin,
including co-payments, deductibles, or coinsurance, to $75 or less, regardless of the type
or amount of new text begin covered new text end insulin prescribed;

(4) not having received an urgent-need supply of new text begin covered new text end insulin through this program
within the previous 12 months, unless authorized under subdivision 9; and

(5) being in urgent need of new text begin covered new text end insulin.

(b) For purposes of this subdivision, "urgent need of new text begin covered new text end insulin" means having
readily available for use less than a seven-day supply of new text begin covered new text end insulin and in need of new text begin
covered new text end insulin in order to avoid the likelihood of suffering significant health consequences.

Sec. 4.

Minnesota Statutes 2024, section 151.74, subdivision 3, is amended to read:

Subd. 3.

Access to urgent-need new text begin covered new text end insulin.

(a) MNsure shall develop an application
form to be used by an individual who is in urgent need of new text begin covered new text end insulin. The application
must ask the individual to attest to the eligibility requirements described in subdivision 2.
The form shall be accessible through MNsure's website. MNsure shall also make the form
available to pharmacies and health care providers who prescribe or dispense new text begin covered new text end insulin,
hospital emergency departments, urgent care clinics, and community health clinics. By
submitting a completed, signed, and dated application to a pharmacy, the individual attests
that the information contained in the application is correct.

(b) If the individual is in urgent need of new text begin covered new text end insulin, the individual may present a
completed, signed, and dated application form to a pharmacy. The individual must also:

(1) have a deleted text begin valid deleted text end new text begin covered new text end insulin prescription; and

(2) present the pharmacist with identification indicating Minnesota residency in the form
of a valid Minnesota identification card, driver's license or permit, individual taxpayer
identification number, or Tribal identification card as defined in section 171.072, paragraph
(b). If the individual in urgent need of new text begin covered new text end insulin is under the age of 18, the individual's
parent or legal guardian must provide the pharmacist with proof of residency.

(c) Upon receipt of a completed and signed application, the pharmacist shall dispense
the deleted text begin prescribed deleted text end new text begin covered new text end insulin in an amount that will provide the individual with a 30-day
supply. The pharmacy must notify the health care practitioner who issued the prescription
order no later than 72 hours after the new text begin covered new text end insulin is dispensed.

(d) The pharmacy may submit to the manufacturer of the dispensed new text begin covered new text end insulin
product or to the manufacturer's vendor a claim for payment that is in accordance with the
National Council for Prescription Drug Program standards for electronic claims processing,
unless the manufacturer agrees to send to the pharmacy a replacement supply of the same
new text begin covered new text end insulin as dispensed in the amount dispensed. If the pharmacy submits an electronic
claim to the manufacturer or the manufacturer's vendor, the manufacturer or vendor shall
reimburse the pharmacy in an amount that covers the pharmacy's acquisition cost.

(e) The pharmacy may collect deleted text begin an deleted text end new text begin a covered new text end insulin co-payment from the individual to
cover the pharmacy's costs of processing and dispensing in an amount not to exceed $35
for the 30-day supply of new text begin covered new text end insulin dispensed.

(f) The pharmacy shall also provide each eligible individual with the information sheet
described in subdivision 7 and a list of trained navigators provided by the Board of Pharmacy
for the individual to contact if the individual needs to access ongoing new text begin covered new text end insulin
coverage options, including assistance in:

(1) applying for medical assistance or MinnesotaCare;

(2) applying for a qualified health plan offered through MNsure, subject to open and
special enrollment periods;

(3) accessing information on providers who participate in prescription drug discount
programs, including providers who are authorized to participate in the 340B program under
section 340b of the federal Public Health Services Act, United States Code, title 42, section
256b; and

(4) accessing new text begin covered new text end insulin manufacturers' patient assistance programs, co-payment
assistance programs, and other foundation-based programs.

(g) The pharmacist shall retain a copy of the application form submitted by the individual
to the pharmacy for reporting and auditing purposes.

(h) A manufacturer may submit to the commissioner of administration a request for
reimbursement in an amount not to exceed $35 for each 30-day supply of new text begin covered new text end insulin
the manufacturer provides under paragraph (d). The commissioner of administration shall
determine the manner and format for submitting and processing requests for reimbursement.
After receiving a reimbursement request, the commissioner of administration shall reimburse
the manufacturer in an amount not to exceed $35 for each 30-day supply of new text begin covered new text end insulin
the manufacturer provided under paragraph (d).

Sec. 5.

Minnesota Statutes 2024, section 151.74, subdivision 4, is amended to read:

Subd. 4.

Continuing safety net program; general.

(a) Each manufacturer shall make
a patient assistance program available to any individual who meets the requirements of this
subdivision. Each manufacturer's patient assistance programs must meet the requirements
of this section. Each manufacturer shall provide the Board of Pharmacy with information
regarding the manufacturer's patient assistance program, including contact information for
individuals to call for assistance in accessing their patient assistance program.

(b) To be eligible to participate in a manufacturer's patient assistance program, the
individual must:

(1) be a Minnesota resident with a valid Minnesota identification card that indicates
Minnesota residency in the form of a Minnesota identification card, driver's license or
permit, individual taxpayer identification number, or Tribal identification card as defined
in section 171.072, paragraph (b). If the individual is under the age of 18, the individual's
parent or legal guardian must provide proof of residency;

(2) have a family income that is equal to or less than 400 percent of the federal poverty
guidelines;

(3) not be enrolled in medical assistance or MinnesotaCare;

(4) not be eligible to receive health care through a federally funded program or receive
prescription drug benefits through the Department of Veterans Affairs; and

(5) not be enrolled in prescription drug coverage through an individual or group health
plan that limits the total amount of cost-sharing that an enrollee is required to pay for a
30-day supply of new text begin covered new text end insulin, including co-payments, deductibles, or coinsurance to
$75 or less, regardless of the type or amount of new text begin covered new text end insulin needed.

(c) Notwithstanding the requirement in paragraph (b), clause (4), an individual who is
enrolled in Medicare Part D is eligible for a manufacturer's patient assistance program if
the individual has spent $1,000 on prescription drugs in the current calendar year and meets
the eligibility requirements in paragraph (b), clauses (1) to (3).

(d) An individual who is interested in participating in a manufacturer's patient assistance
program may apply directly to the manufacturer; apply through the individual's health care
practitioner, if the practitioner participates; or contact a trained navigator for assistance in
finding a long-term new text begin covered new text end insulin supply solution, including assistance in applying to a
manufacturer's patient assistance program.

Sec. 6.

Minnesota Statutes 2024, section 151.74, subdivision 5, is amended to read:

Subd. 5.

Continuing safety net program; manufacturer's responsibilities.

(a) Upon
receipt of an application for the manufacturer's patient assistance program, the manufacturer
shall process the application and determine eligibility. The manufacturer shall notify the
applicant of the determination within ten business days of receipt of the application. If
necessary, the manufacturer may request additional information from the applicant. If
additional information is needed, the manufacturer must notify the applicant within five
business days of receipt of the application as to what information is being requested. Within
three business days of receipt of the requested information, the manufacturer must determine
eligibility and notify the applicant of the determination. If the individual has been determined
to be not eligible, the manufacturer must include the reasons for denying eligibility in the
notification. The individual may seek an appeal of the determination in accordance with
subdivision 8.

(b) If the individual is determined to be eligible, the manufacturer shall provide the
individual with an eligibility statement or other indication that the individual has been
determined eligible for the manufacturer's patient assistance program. An individual's
eligibility is valid for 12 months and is renewable upon a redetermination of eligibility.

(c) If the eligible individual has prescription drug coverage through an individual or
group health plan, the manufacturer may determine that the individual's new text begin covered new text end insulin
needs are better addressed through the use of the manufacturer's co-payment assistance
program, in which case, the manufacturer shall inform the individual and provide the
individual with the necessary coupons to submit to a pharmacy. In no instance shall an
eligible individual be required to pay more than the co-payment amount specified under
subdivision 6, paragraph (e).

Sec. 7.

Minnesota Statutes 2024, section 151.74, subdivision 6, is amended to read:

Subd. 6.

Continuing safety net program; process.

(a) The individual shall submit to
a pharmacy the statement of eligibility provided by the manufacturer under subdivision 5,
paragraph (b). Upon receipt of an individual's eligibility status, the pharmacy shall submit
an order containing the name of the new text begin covered new text end insulin product and the daily dosage amount
as contained in a valid prescription to the product's manufacturer.

(b) The pharmacy must include with the order to the manufacturer the following
information:

(1) the pharmacy's name and shipping address;

(2) the pharmacy's office telephone number, fax number, email address, and contact
name; and

(3) any specific days or times when deliveries are not accepted by the pharmacy.

(c) Upon receipt of an order from a pharmacy and the information described in paragraph
(b), the manufacturer shall send to the pharmacy a 90-day supply of new text begin covered new text end insulin as
ordered, unless a lesser amount is requested in the order, at no charge to the individual or
pharmacy.

(d) Except as authorized under paragraph (e), the pharmacy shall provide the new text begin covered
new text end insulin to the individual at no charge to the individual. The pharmacy shall not provide
new text begin covered new text end insulin received from the manufacturer to any individual other than the individual
associated with the specific order. The pharmacy shall not seek reimbursement for the new text begin
covered new text end insulin received from the manufacturer or from any third-party payer.

(e) The pharmacy may collect a co-payment from the individual to cover the pharmacy's
costs for processing and dispensing in an amount not to exceed $50 for each 90-day supply
if the new text begin covered new text end insulin is sent to the pharmacy.

(f) The pharmacy may submit to a manufacturer a reorder for an individual if the
individual's eligibility statement has not expired. Upon receipt of a reorder from a pharmacy,
the manufacturer must send to the pharmacy an additional 90-day supply of the product,
unless a lesser amount is requested, at no charge to the individual or pharmacy if the
individual's eligibility statement has not expired.

(g) Notwithstanding paragraph (c), a manufacturer may send the new text begin covered new text end insulin as
ordered directly to the individual if the manufacturer provides a mail order service option.

(h) A manufacturer may submit to the commissioner of administration a request for
reimbursement in an amount not to exceed $105 for each 90-day supply of new text begin covered new text end insulin
the manufacturer provides under paragraphs (c) and (f). The commissioner of administration
shall determine the manner and format for submitting and processing requests for
reimbursement. After receiving a reimbursement request, the commissioner of administration
shall reimburse the manufacturer in an amount not to exceed $105 for each 90-day supply
of new text begin covered new text end insulin the manufacturer provided under paragraphs (c) and (f). If the manufacturer
provides less than a 90-day supply of new text begin covered new text end insulin under paragraphs (c) and (f), the
manufacturer may submit a request for reimbursement not to exceed $35 for each 30-day
supply of new text begin covered new text end insulin provided.

Sec. 8.

Minnesota Statutes 2024, section 151.74, subdivision 7, is amended to read:

Subd. 7.

Board of Pharmacy and MNsure responsibilities.

(a) The Board of Pharmacy
shall develop an information sheet to post on its website and provide a link to the information
sheet on the board's website for pharmacies, health care practitioners, hospital emergency
departments, urgent care clinics, and community health clinics. The information sheet must
contain:

(1) a description of the urgent-need new text begin covered new text end insulin safety net program, including how
to access the program;

(2) a description of each new text begin covered new text end insulin manufacturer's patient assistance program and
cost-sharing assistance program, including contact information on accessing the assistance
programs for each manufacturer;

(3) information on how to contact a trained navigator for assistance in applying for
medical assistance, MinnesotaCare, a qualified health plan, or deleted text begin an deleted text end new text begin a covered new text end insulin
manufacturer's patient assistance programs;

(4) information on how to contact the Board of Pharmacy if a manufacturer determines
that an individual is not eligible for the manufacturer's patient assistance program; and

(5) notification that an individual in need of assistance may contact their local county
social service department for more information or assistance in accessing ongoing affordable
new text begin covered new text end insulin options.

(b) The board shall also inform each individual who accesses urgent-need new text begin covered new text end insulin
through the insulin safety net program or accesses a manufacturer's patient assistance program
that the individual may participate in a survey conducted by the Department of Health
regarding satisfaction with the program. The board shall provide contact information for
the individual to learn more about the survey and how to participate. This information may
be included on the information sheet described in paragraph (a).

(c) MNsure, in consultation with the Board of Pharmacy and the commissioner of human
services, shall develop a training program for navigators to provide navigators with
information and resources necessary to assist individuals in accessing appropriate long-term
new text begin covered new text end insulin options.

(d) MNsure, in consultation with the Board of Pharmacy, shall compile a list of navigators
who have completed the training program and who are available to assist individuals in
accessing affordable new text begin covered new text end insulin coverage options. The list shall be made available
through the board's website and to pharmacies and health care practitioners who dispense
and prescribe new text begin covered new text end insulin.

(e) If a navigator assists an individual in accessing deleted text begin an deleted text end new text begin a covered new text end insulin manufacturer's
patient assistance program, MNsure, within the available appropriation, shall pay the
navigator a onetime application assistance bonus of no less than $25. If a navigator receives
a payment per enrollee of an assistance bonus under section 62V.05, subdivision 4, or
256.962, subdivision 5, the navigator shall not receive compensation under this paragraph.

Sec. 9.

Minnesota Statutes 2024, section 151.74, subdivision 9, is amended to read:

Subd. 9.

Additional 30-day urgent-need new text begin covered new text end insulin supply.

(a) If an individual
has applied for medical assistance or MinnesotaCare but has not been determined eligible
or has been determined eligible but coverage has not become effective or the individual has
been determined ineligible for the manufacturer's patient assistance program by the
manufacturer and the individual has requested a review pursuant to subdivision 8 but the
panel has not rendered a decision, the individual may access urgent-need new text begin covered new text end insulin
under subdivision 3 if the individual is in urgent need of new text begin covered new text end insulin as defined under
subdivision 2, paragraph (b).

(b) To access an additional 30-day supply of new text begin covered new text end insulin, the individual must attest
to the pharmacy that the individual meets the requirements of paragraph (a) and must comply
with subdivision 3, paragraph (b).

Sec. 10.

Minnesota Statutes 2024, section 151.74, subdivision 10, is amended to read:

Subd. 10.

Penalty.

(a) If a manufacturer fails to comply with this section, the board may
assess an administrative penalty of $200,000 per month of noncompliance, with the penalty
increasing to $400,000 per month if the manufacturer continues to be in noncompliance
after six months, and increasing to $600,000 per month if the manufacturer continues to be
in noncompliance after one year. The penalty shall remain at $600,000 per month for as
long as the manufacturer continues to be in noncompliance.

(b) In addition, a manufacturer is subject to the administrative penalties specified in
paragraph (a) if the manufacturer fails to:

(1) provide a hotline for individuals to call or access between 8 a.m. and 10 p.m. on
weekdays and between 10 a.m. and 6 p.m. on Saturdays; and

(2) list on the manufacturer's website the eligibility requirements for the manufacturer's
patient assistance programs for Minnesota residents.

(c) Any penalty assessed under this subdivision shall be deposited in a separate new text begin covered new text end
insulin assistance account in the special revenue fund.

Sec. 11.

Minnesota Statutes 2024, section 151.74, subdivision 11, is amended to read:

Subd. 11.

Data.

(a) Any data collected, created, received, maintained, or disseminated
by the Board of Pharmacy, the legislative auditor, the commissioner of health, MNsure, or
a trained navigator under this section related to an individual who is seeking to access
urgent-need new text begin covered new text end insulin or participate in a manufacturer's patient assistance program
under this section is classified as private data on individuals as defined in section 13.02,
subdivision 12, and may not be retained for longer than ten years.

(b) A manufacturer must maintain the privacy of all data received from any individual
applying for the manufacturer's patient assistance program under this section and is prohibited
from selling, sharing, or disseminating data received under this section unless required to
under this section or the individual has provided the manufacturer with a signed authorization.

Sec. 12.

Minnesota Statutes 2024, section 151.74, subdivision 13, is amended to read:

Subd. 13.

Reports.

(a) By February 15 of each year, deleted text begin beginning February 15, 2021, deleted text end each
manufacturer shall report to the Board of Pharmacy the following:

(1) the number of Minnesota residents who accessed and received new text begin covered new text end insulin on
an urgent-need basis under this section in the preceding calendar year;

(2) the number of Minnesota residents participating in the manufacturer's patient
assistance program in the preceding calendar year, including the number of Minnesota
residents who the manufacturer determined were ineligible for their patient assistance
program; and

(3) the value of the new text begin covered new text end insulin provided by the manufacturer under clauses (1) and
(2).

For purposes of this paragraph, "value" means the wholesale acquisition cost of the new text begin covered new text end
insulin provided.

(b) By March 15 of each year, deleted text begin beginning March 15, 2021, deleted text end the Board of Pharmacy shall
submit the information reported in paragraph (a) to the chairs and ranking minority members
of the legislative committees with jurisdiction over health and human services policy and
finance. The board shall also include in the report any administrative penalties assessed
under subdivision 10, including the name of the manufacturer and amount of the penalty
assessed.

Sec. 13.

Minnesota Statutes 2024, section 151.74, subdivision 14, is amended to read:

Subd. 14.

Program review; legislative auditor.

(a) The legislative auditor is requested
to conduct a program review to determine:

(1) whether the manufacturers are meeting the responsibilities required under this section,
including but not limited to:

(i) reimbursing pharmacies for urgent-need new text begin covered new text end insulin dispensed under subdivision
3;

(ii) determining eligibility in a timely manner and notifying the individuals as required
under subdivision 5; and

(iii) providing pharmacies with new text begin covered new text end insulin product under the manufacturers' patient
assistance programs; and

(2) whether the training program developed for navigators is adequate and easily
accessible for navigators interested in becoming trained, and that there is a sufficient number
of trained navigators to provide assistance to individuals in need of assistance.

(b) The legislative auditor may access application forms retained by pharmacies under
subdivision 3, paragraph (g), to determine whether urgent-need new text begin covered new text end insulin is being
dispensed in accordance with this section.

Sec. 14.

Minnesota Statutes 2024, section 151.741, subdivision 1, is amended to read:

Subdivision 1.

Definitions.

(a) For purposes of this section, the following terms have
the meanings given.

(b) "Board" means the Minnesota Board of Pharmacy under section 151.02.

new text begin (c) "Covered insulin" has the meaning given in section 151.74, subdivision 1.
new text end

deleted text begin (c) deleted text end new text begin (d) new text end "Manufacturer" means a manufacturer licensed under section 151.252 and engaged
in the manufacturing of deleted text begin prescription deleted text end new text begin covered new text end insulin.

Sec. 15.

Minnesota Statutes 2024, section 151.741, subdivision 2, is amended to read:

Subd. 2.

Assessment of registration fee.

(a) The board shall assess each manufacturer
an annual registration fee of $100,000, except as provided in paragraph (b). The board shall
notify each manufacturer of this requirement beginning November 1, 2024, and each
November 1 thereafter.

(b) A manufacturer may request an exemption from the annual registration fee. The
board shall exempt a manufacturer from the annual registration fee if the manufacturer can
demonstrate to the board, in the form and manner specified by the board, that gross revenue
from sales of deleted text begin prescription deleted text end new text begin covered new text end insulin produced by that manufacturer and sold or
delivered within or into Minnesota was less than five percent of the total gross revenue from
sales of deleted text begin prescription deleted text end new text begin covered new text end insulin produced by all manufacturers and sold or delivered
within or into Minnesota in the previous calendar year.

Sec. 16.

Minnesota Statutes 2025 Supplement, section 151.741, subdivision 5, is amended
to read:

Subd. 5.

Insulin repayment account; annual transfer from health care access fund.

(a)
The insulin repayment account is established in the special revenue fund in the state treasury.
Money in the account is appropriated each fiscal year to the commissioner of administration
to reimburse manufacturers for new text begin covered new text end insulin dispensed under the insulin safety net program
in section 151.74, in accordance with section 151.74, subdivisions 3, paragraph (h), and 6,
paragraph (h), and to cover costs incurred by the commissioner in providing these
reimbursement payments.

(b) By June 30, 2025, and each June 30 thereafter, the commissioner of administration
shall certify to the commissioner of management and budget the total amount expended in
the prior fiscal year for:

(1) reimbursement to manufacturers for new text begin covered new text end insulin dispensed under the insulin
safety net program in section 151.74, in accordance with section 151.74, subdivisions 3,
paragraph (h), and 6, paragraph (h); and

(2) costs incurred by the commissioner of administration in providing the reimbursement
payments described in clause (1).

(c) The commissioner of management and budget shall transfer from the health care
access fund to the insulin repayment account, beginning July 1, 2025, and each July 1
thereafter, an amount equal to the amount to which the commissioner of administration
certified pursuant to paragraph (b).

Sec. 17. new text begin REPEALER.
new text end

new text begin Minnesota Statutes 2024, section 151.74, subdivision 15, new text end new text begin is repealed.
new text end

APPENDIX

Repealed Minnesota Statutes: 26-06583

151.74 INSULIN SAFETY NET PROGRAM.

Subd. 15.

Program satisfaction; surveys.

(a) The commissioner of health, in consultation with the Board of Pharmacy and individuals who are insulin-dependent, shall develop and conduct a survey of individuals who have accessed urgent-need insulin through the program and who are accessing or have accessed a manufacturer's patient assistance program since the commencement of the insulin safety net program; and a survey of pharmacies that have dispensed insulin on an urgent-need basis under the program and have participated in the manufacturers' patient assistance programs under this section.

(b) The survey for individuals shall cover overall satisfaction with the program, including but not limited to:

(1) accessibility to urgent-need insulin;

(2) adequacy of the information sheet and list of navigators received from the pharmacy;

(3) whether the individual contacted a trained navigator and, if so, if the navigator was helpful and knowledgeable;

(4) whether the individual accessed the manufacturer's patient assistance program and, if so, how easy it was to access application forms, apply to the manufacturer's programs, and receive the insulin product from the pharmacy; and

(5) whether the individual is still in need of a long-term solution for affordable insulin.

(c) The survey for the pharmacies shall include, but is not limited to:

(1) timeliness of reimbursement from the manufacturers for urgent-need insulin dispensed by the pharmacy;

(2) ease in submitting insulin product orders to the manufacturers; and

(3) timeliness of receiving insulin orders from the manufacturers.

(d) The commissioner may contract with a nonprofit entity to develop and conduct the survey and to evaluate the survey results.

(e) By January 15, 2022, the commissioner shall submit a report to the chairs and ranking minority members of the legislative committees with jurisdiction over health and human services policy and finance containing the results of the surveys.